Enanta Pharmaceuticals
ENTA
131 hedge funds and large institutions have $416M invested in Enanta Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 45 increasing their positions, 28 reducing their positions, and 24 closing their positions.
8,244% more call options, than puts
Call options by funds: $2.09M | Put options by funds: $25K
83% more capital invested
Capital invested by funds: $227M → $416M (+$189M)
61% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 28
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
8% more funds holding
Funds holding: 121 → 131 (+10)
2.59% more ownership
Funds ownership: 88.84% → 91.43% (+2.6%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$24.9M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$22.6M |
| 3 |
BlackRock
New York
|
+$15.8M |
| 4 |
KAM
Krensavage Asset Management
New York
|
+$8.28M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$9.58M |
| 2 |
Millennium Management
New York
|
-$3.53M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.6M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.02M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$1.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
S
151
Sachetta
Lynnfield,
Massachusetts
| – | -$1.2K | -100 | Closed |
|
152
Jones Financial Companies
Des Peres,
Missouri
| – | -$474 | -60 | Closed |
|
|
CA
153
Clearstead Advisors
Cleveland,
Ohio
| – | -$671 | -56 | Closed |
|
|
ASN
154
Advisory Services Network
Atlanta,
Georgia
| – | -$48 | -4 | Closed |
|
|
C
155
Covestor
London,
United Kingdom
| – | -$13 | -1 | -6% |
|
ENTA Hedge Fund Activity: Q4 2025 in Review
131 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2025, worth a combined $416M — up 83% from $227M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ENTA positions and 24 closed out — a net gain of 12 holders — while 45 added to existing stakes and 28 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $24.9M. The largest seller was Commodore Capital, exiting entirely with an estimated $9.58M sold.
- 131 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2025, up from 121 in Q3 2025.
- Funds reported $416M of Enanta Pharmaceuticals stock for Q4 2025, up 83% quarter-over-quarter.
- 36 funds opened new Enanta Pharmaceuticals positions in Q4 2025 and 24 closed out, a net change of +12 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2025 was Deep Track Capital, an estimated $24.9M added.
- The largest Enanta Pharmaceuticals seller in Q4 2025 was Commodore Capital, an estimated $9.58M sold.
Based on aggregated 13F filings for Q4 2025.